drugset / Trial / NCT05654298

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

NCT05654298

Completed 20 enrolled Universitaire Ziekenhuizen KU Leuven
RandomizedCrossoverTriple-blindBasic science

Summary

The involvement of calcitonin gene-related peptide (CGRP) in the cinnamaldehyde-induced dermal blood flow increase and in the mechanism of action of triptans will be investigated. The capsaicin-induced dermal blood flow will be incorporated as a positive control; histamine skin pricks as a negative control. Changes in dermal blood flow will be measured with laser speckle contrast imaging.

Timeline

Start
2022-03-15
Primary completion
2023-03-15
Completion
2023-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Sumatriptan Unknown 100 mg
Subject Ubrogepant Small molecule 100 mg

Indications